Hodgkin's Disease
- 5 March 1992
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 326 (10) , 678-687
- https://doi.org/10.1056/nejm199203053261006
Abstract
IN 1992, approximately 75 percent of all patients who present with Hodgkin's disease should be cured of their disease. This result will be achieved only with the careful application of appropriate staging techniques and treatment methods.Cell of OriginHodgkin's disease is unusual in that the bulk of the tumor is composed of normal cells within which the malignant Reed–Sternberg cells are found. The cellular origin of the neoplastic cell remains controversial.1 The Reed–Sternberg cells in all the histologic subtypes usually express antigens found on resting or activated lymphocytes. These include CD30 (Ki-1, Hefi-1), CD25 (interleukin-2 receptor), HLA-DR, and CD71 . . .Keywords
This publication has 100 references indexed in Scilit:
- Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.BMJ, 1990
- Leukemia Following Hodgkin's DiseaseNew England Journal of Medicine, 1990
- Hodgkin's Disease and Epstein-Barr VirusNew England Journal of Medicine, 1989
- Risk of Second Cancers after Treatment for Hodgkin's DiseaseNew England Journal of Medicine, 1988
- Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's DiseaseNew England Journal of Medicine, 1987
- Concomitant illness in patients treated for Hodgkin's diseaseCancer Treatment Reviews, 1986
- Acute leukaemia in patients treated for Hodgkin's diseaseBritish Journal of Haematology, 1984
- Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's diseaseCancer, 1983
- Occurrence of Non-Hodgkin's Lymphoma after Therapy for Hodgkin's DiseaseNew England Journal of Medicine, 1979
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975